Collegium Pharmaceutical, Inc. (COLL) Balance Sheet
COLL balance sheet, 2025
December 31, 2025 · U.S. dollars$1.66B assets = $1.36B liabilities + $301.7M equity
Both columns are drawn to the same scale: what COLL owns equals what it owes plus shareholders’ equity. Hover a block for its value.
COLL financial health
Descriptive bands, not a rating. Fiscal 2025.
COLL balance sheet trends, 2016–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $162.0M2016 | $1.66B2025 | +29.5%/yr | |
| Total liabilities | $27.1M2016 | $1.36B2025 | +54.4%/yr | |
| Shareholders’ equity | $134.9M2016 | $301.7M2025 | +9.4%/yr | |
| Cash & short-term investments | $153.2M2016 | $406.5M2025 | +11.5%/yr | |
| Total debt | $4.2M2016 | $940.6M2025 | +82.5%/yr | |
| Net cash (debt) | $149.0M2016 | −$534.0M2025 | −$683.1M | |
| Working capital | $135.6M2016 | $251.4M2025 | +$115.7M | |
| Book value per share | $5.562016 | $7.602025 | +3.5%/yr | |
| Current ratio | 6.922016 | 1.572025 | −5.34 | |
| Debt / equity | 0.032016 | 3.122025 | +3.09 | |
| Shares outstanding | 24.3M2016 | 39.7M2025 | +5.6%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
COLL assets
COLL liabilities and equity
COLL debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
COLL balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & short-term investments | $406.5M | $162.8M | $310.5M | $173.7M | $186.4M | $174.1M | $170.0M | $146.6M | $118.7M | $153.2M |
| Cash & equivalents | $251.1M | $70.6M | $238.9M | $173.7M | $186.4M | $174.1M | $170.0M | $146.6M | $118.7M | $153.2M |
| Short-term investments | $155.4M | $92.2M | $71.6M | $0 | — | — | — | — | $0 | $0 |
| Receivables | $211.3M | $228.5M | $179.5M | $183.1M | $105.8M | $83.3M | $73.0M | $77.9M | $10.0M | $2.1M |
| Inventory | $40.9M | $35.6M | $32.3M | $46.5M | $17.4M | $15.6M | $9.6M | $7.8M | $1.8M | $1.3M |
| Other current assets | $32.6M | $55.4M | $15.2M | $16.7M | $5.9M | $4.8M | $3.1M | $5.1M | $3.0M | $1.9M |
| Total current assets | $691.4M | $482.3M | $537.6M | $420.0M | $315.5M | $277.9M | $255.7M | $237.5M | $133.5M | $158.6M |
| Property, plant & equipment (net) | $16.2M | $20.2M | $22.0M | $26.4M | $27.1M | $27.4M | $20.9M | $9.3M | $1.8M | $1.0M |
| Goodwill & intangible assets | $815.4M | $1.05B | $555.6M | $701.2M | $268.7M | $335.9M | $29.5M | $44.3M | $0 | $2.1M |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $133.8M | $107.4M | $28.1M | $26.6M | $80.7M | $2.7M | $178,000 | $204,000 | $258,000 | $301,000 |
| Total assets | $1.66B | $1.66B | $1.14B | $1.17B | $692.1M | $643.8M | $306.3M | $291.2M | $135.6M | $162.0M |
| Liabilities | ||||||||||
| Accounts payable | $10.7M | $3.9M | $8.7M | $3.5M | $4.2M | $10.0M | $6.2M | $12.2M | $5.7M | $18.0M |
| Short-term debt | $30.4M | $65.9M | $184.3M | $163.6M | $49.2M | $48.2M | $4.5M | $1.6M | $1.5M | $2.7M |
| Deferred revenue | $667,000 | $10.0M | −$16.0M | — | — | — | — | — | — | $4.9M |
| Total current liabilities | $440.0M | $509.5M | $457.9M | $433.7M | $279.6M | $239.5M | $201.8M | $187.5M | $31.5M | $22.9M |
| Long-term debt | $780.3M | $787.9M | $483.8M | $538.5M | $201.6M | $209.6M | $7.7M | $9.9M | $0 | $1.5M |
| Lease obligations | $5.5M | $6.8M | $7.1M | $8.2M | $8.8M | $9.5M | $10.1M | — | — | $34,000 |
| Other long-term liabilities | $134.8M | $137.3M | $6.1M | $7.1M | $8.0M | $8.8M | $9.4M | $2.3M | $7.2M | $2.7M |
| Total liabilities | $1.36B | $1.43B | $947.9M | $979.3M | $489.1M | $457.8M | $218.9M | $199.7M | $31.5M | $27.1M |
| Shareholders' equity | ||||||||||
| Common stock & paid-in capital | $41,000 | $40,000 | $38,000 | $37,000 | $36,000 | $35,000 | $34,000 | $33,000 | $33,000 | $29,000 |
| Retained earnings (deficit) | −$101.1M | −$164.0M | −$233.2M | −$281.3M | −$256.3M | −$333.1M | −$359.9M | −$337.2M | −$298.0M | −$223.2M |
| Treasury stock | — | — | — | — | −$42.9M | — | — | — | $0 | $0 |
| Accumulated other comprehensive income | $319,000 | $55,000 | $14,000 | $0 | $0 | $0 | −$2.3M | −$1.8M | −$1.7M | −$1.3M |
| Minority interest | — | — | — | — | — | — | — | — | $0 | $0 |
| Total shareholders' equity | $301.7M | $228.8M | $195.4M | $194.8M | $202.9M | $186.0M | $87.4M | $91.6M | $104.1M | $134.9M |
| Key figures | ||||||||||
| Total debt | $940.6M | $859.3M | $674.3M | $709.2M | $258.8M | $266.6M | $21.6M | $11.5M | $1.5M | $4.2M |
| Net cash (debt) | −$534.0M | −$696.5M | −$363.7M | −$535.5M | −$72.3M | −$92.5M | $148.4M | $135.1M | $117.2M | $149.0M |
| Working capital | $251.4M | −$27.3M | $79.7M | −$13.7M | $36.0M | $38.4M | $54.0M | $50.0M | $102.0M | $135.6M |
| Tangible book value | −$513.8M | −$824.9M | −$360.1M | −$506.3M | −$65.8M | −$149.9M | $57.9M | $47.3M | $104.1M | $132.8M |
| Book value per share | $7.60 | $5.66 | $4.68 | $5.76 | $4.94 | $5.29 | $2.61 | $2.78 | $3.44 | $5.56 |
| Shares outstanding | 39.7M | 40.4M | 41.8M | 33.8M | 41.0M | 35.2M | 33.5M | 33.0M | 30.3M | 24.3M |
| Current ratio | 1.57 | 0.95 | 1.17 | 0.97 | 1.13 | 1.16 | 1.27 | 1.27 | 4.24 | 6.92 |
| Quick ratio | 1.40 | 0.77 | 1.07 | 0.82 | 1.05 | 1.08 | 1.20 | 1.20 | 4.09 | 6.78 |
| Debt / equity | 3.12 | 3.75 | 3.45 | 3.64 | 1.28 | 1.43 | 0.25 | 0.13 | 0.01 | 0.03 |
| Equity / assets | 18.2% | 13.8% | 17.1% | 16.6% | 29.3% | 28.9% | 28.5% | 31.4% | 76.8% | 83.3% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $129.5M | $421.8M | $406.5M | $305.7M | $222.2M | $197.8M | $162.8M | $120.0M | $271.6M | $318.0M | $310.5M | $304.6M |
| Cash & equivalents | $129.5M | $268.6M | $251.1M | $169.9M | $117.3M | $96.2M | $70.6M | $39.0M | $172.9M | $228.6M | $238.9M | $258.5M |
| Short-term investments | $0 | $153.1M | $155.4M | $135.8M | $104.8M | $101.6M | $92.2M | $81.0M | $98.7M | $89.4M | $71.6M | $46.0M |
| Receivables | $285.1M | $228.8M | $211.3M | $233.9M | $213.0M | $228.7M | $228.5M | $228.5M | $183.9M | $174.7M | $179.5M | $181.9M |
| Inventory | $113.3M | $42.7M | $40.9M | $38.1M | $38.1M | $37.2M | $35.6M | $38.0M | $27.9M | $31.3M | $32.3M | $34.1M |
| Other current assets | $80.2M | $52.4M | $32.6M | $36.2M | $75.9M | $63.9M | $55.4M | $57.4M | $26.9M | $15.2M | $15.2M | $16.5M |
| Total current assets | $608.0M | $745.7M | $691.4M | $613.9M | $549.2M | $527.6M | $482.3M | $443.8M | $510.2M | $539.3M | $537.6M | $537.1M |
| Property, plant & equipment (net) | $14.4M | $15.6M | $16.2M | $16.7M | $18.2M | $19.4M | $20.2M | $20.8M | $20.6M | $21.3M | $22.0M | $22.9M |
| Goodwill & intangible assets | $1.38B | $760.0M | $815.4M | $870.9M | $928.4M | $986.7M | $1.05B | $1.09B | $486.5M | $521.0M | $555.6M | $590.1M |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $137.1M | $130.7M | $133.8M | $105.9M | $96.9M | $97.8M | $107.4M | $77.7M | $36.1M | $32.7M | $28.1M | $27.5M |
| Total assets | $2.14B | $1.65B | $1.66B | $1.61B | $1.59B | $1.63B | $1.66B | $1.64B | $1.05B | $1.11B | $1.14B | $1.18B |
| Liabilities | ||||||||||||
| Accounts payable | $9.2M | $6.8M | $10.7M | $7.6M | $10.9M | $17.9M | $3.9M | $3.1M | $2.4M | $6.0M | $8.7M | $3.7M |
| Short-term debt | $56.6M | $34.1M | $30.4M | $66.0M | $65.9M | $65.9M | $65.9M | $65.9M | $184.4M | $184.3M | $184.3M | $184.3M |
| Deferred revenue | $667,000 | $667,000 | $667,000 | $667,000 | — | $10.0M | $10.0M | $34.9M | $532,000 | $14.1M | — | — |
| Total current liabilities | $589.9M | $435.0M | $440.0M | $452.9M | $464.6M | $486.7M | $509.5M | $459.4M | $461.7M | $446.4M | $457.9M | $464.6M |
| Long-term debt | $1.04B | $770.2M | $780.3M | $743.5M | $758.3M | $773.1M | $787.9M | $802.6M | $369.5M | $439.8M | $483.8M | $527.7M |
| Lease obligations | $5.0M | $5.2M | $5.5M | $5.9M | $6.2M | $6.5M | $6.8M | $7.2M | $6.6M | $6.9M | $7.1M | $7.3M |
| Other long-term liabilities | $197.5M | $134.4M | $134.8M | $136.1M | $137.5M | $137.1M | $137.3M | $138.8M | $5.6M | $5.9M | $6.1M | $6.4M |
| Total liabilities | $1.82B | $1.34B | $1.36B | $1.33B | $1.36B | $1.40B | $1.43B | $1.40B | $836.8M | $892.1M | $947.9M | $998.7M |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | $41,000 | $41,000 | $41,000 | $41,000 | $40,000 | $40,000 | $40,000 | $40,000 | $40,000 | $39,000 | $38,000 | $38,000 |
| Retained earnings (deficit) | −$101.7M | −$86.6M | −$101.1M | −$118.1M | −$149.6M | −$161.6M | −$164.0M | −$176.5M | −$185.9M | −$205.5M | −$233.2M | −$265.1M |
| Accumulated other comprehensive income | — | −$219,000 | $319,000 | $292,000 | $337,000 | $241,000 | $55,000 | $393,000 | −$182,000 | −$124,000 | $14,000 | −$52,000 |
| Total shareholders' equity | $311.9M | $312.4M | $301.7M | $274.8M | $232.2M | $234.4M | $228.8M | $234.3M | $216.6M | $222.2M | $195.4M | $178.9M |
| Key figures | ||||||||||||
| Total debt | $857.8M | $808.1M | $940.6M | $936.3M | $829.1M | $844.2M | $859.3M | $874.4M | $559.5M | $630.0M | $674.3M | $718.4M |
| Net cash (debt) | −$728.3M | −$386.3M | −$534.0M | −$630.6M | −$607.0M | −$646.4M | −$696.5M | −$754.4M | −$287.8M | −$311.9M | −$363.7M | −$413.8M |
| Working capital | $18.2M | $310.7M | $251.4M | $160.9M | $84.6M | $40.8M | −$27.3M | −$15.6M | $48.5M | $92.8M | $79.7M | $72.5M |
| Tangible book value | −$1.06B | −$447.5M | −$513.8M | −$596.1M | −$696.2M | −$752.3M | −$824.9M | −$858.6M | −$269.9M | −$298.9M | −$360.1M | −$411.2M |
| Book value per share | $9.61 | $7.80 | $7.60 | $6.97 | $5.94 | $7.14 | $5.71 | $5.83 | $5.36 | $5.36 | $4.68 | $4.25 |
| Shares outstanding | 32.5M | 40.1M | 39.7M | 39.4M | 39.1M | 32.8M | 40.1M | 40.2M | 40.4M | 41.4M | 41.8M | 42.1M |
| Current ratio | 1.03 | 1.71 | 1.57 | 1.36 | 1.18 | 1.08 | 0.95 | 0.97 | 1.11 | 1.21 | 1.17 | 1.16 |
| Quick ratio | 0.70 | 1.50 | 1.40 | 1.19 | 0.94 | 0.88 | 0.77 | 0.76 | 0.99 | 1.10 | 1.07 | 1.05 |
| Debt / equity | 2.75 | 2.59 | 3.12 | 3.41 | 3.57 | 3.60 | 3.75 | 3.73 | 2.58 | 2.84 | 3.45 | 4.02 |
| Equity / assets | 14.6% | 18.9% | 18.2% | 17.1% | 14.6% | 14.4% | 13.8% | 14.3% | 20.6% | 19.9% | 17.1% | 15.2% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed February 26, 2026); data from EODHD.
COLL financial position
At the end of fiscal 2025 (December 31, 2025), Collegium Pharmaceutical had total assets of $1.7 billion (down 0.4% from a year earlier), total liabilities of $1.4 billion and shareholders' equity of $301.7 million. It held $406.5 million in cash and short-term investments against $940.6 million of debt, net debt of $534.0 million. Its current ratio was 1.57. In the latest quarter (ended June 30, 2026) total assets were $2.1 billion and equity $311.9 million.
Related: COLL income statement, COLL cash flow statement, COLL key metrics. See the COLL stock overview for the latest quote and news.
COLL balance sheet FAQ
What are Collegium Pharmaceutical's total assets?
Collegium Pharmaceutical reported total assets of $1.7 billion at the end of fiscal 2025 (December 31, 2025), compared with $1.7 billion a year earlier.
How much debt does Collegium Pharmaceutical have?
Collegium Pharmaceutical had $940.6 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 3.12.
How much cash does Collegium Pharmaceutical have?
Collegium Pharmaceutical held $406.5 million in cash and short-term investments at the end of fiscal 2025; with $940.6 million of debt that is net debt of $534.0 million.
What is Collegium Pharmaceutical's book value?
Collegium Pharmaceutical's shareholders' equity (book value) was $301.7 million at the end of fiscal 2025, or $7.60 per share.
What is Collegium Pharmaceutical's current ratio?
Collegium Pharmaceutical had current assets of $691.4 million and current liabilities of $440.0 million, a current ratio of 1.57 (it can cover its short-term obligations).
How much goodwill does Collegium Pharmaceutical have?
Collegium Pharmaceutical carried $815.4 million of goodwill and intangible assets, 49.2% of total assets, at the end of fiscal 2025.